Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.
The companies will share bioinformatics and NGS expertise to speed the identification of diseases, accelerate drug discovery, and find "genomic shields."
TwoXar will work with Stanford's Asian Liver Center to identify and validate computationally-derived drug candidates that target hepatocellular carcinomas.
Under the terms of the agreement, Insilico Medicine will integrate unspecified data assets and the staff of Belgian bioinformatics company InSilico Screen.
TwoXar will use the funds to expand its engineering and commercial teams and support partnerships focused on drug candidates for metabolic and neurological diseases.
NEW YORK (GenomeWeb News) – Microbiome company Second Genome today announced a deal with Johnson & Johnson's Janssen Biotech aimed at microbiome drug discovery.
Second Genome also announced it raised an additional $6.5 million in Series A financing.
NEW YORK (GenomeWeb News) – MyoKardia, a San Francisco-based drug startup, has been launched with $38 million in Series A financing from Third Rock Ventures.
